TRIM33 and dermatomyositis: Numerous studies have suggested the presence of anti-TIF1-γ confers a great risk of cancer development in DM (26–28).And data from a large UK-based adult DM cohort found that cancer types differ according to anti-TIF1-Ab status, with female anti-TIF1-Ab-positive patients at increased risk of ovarian cancer (26).